MUMBAI, India, Jan. 9 -- Intellectual Property India has published a patent application (202511113443 A) filed by Shree Guru Gobind Singh Tricentenary University, Gurugram, Haryana, on Nov. 18, 2025, for 'pegylated-2-thienyl-alanine-ornithine-proline (pegylated top) as an angiotensin-converting enzyme (ace) inhibitor and synthesis method thereof.'
Inventor(s) include Dr. Mahesh Kumar Seth; Dr. Rikeshwer Prasad Dewangan; Savita Seth; Mohit Roy; Dr. Promod Mehta; Dr. Brahm Kumar Tiwari; and Dr. Kunal.
The application for the patent was published on Jan. 9, under issue no. 02/2026.
According to the abstract released by the Intellectual Property India: "A Pegylated-2-Thienyl-Alanine-Ornithine-Proline (Pegylated TOP) as an Angiotensin-Converting Enzyme (ACE) inhibitor, offering improved stability, solubility, and therapeutic applicability for the management of hypertension and related cardiovascular conditions, a method for preparing the Pegylated TOP peptide via solid-phase peptide synthesis, involves sequential assembly of protected amino acids onto a solid support, followed by stepwise deprotection and coupling reactions to construct the 2-Thienyl-Alanine-Ornithine-Proline peptide backbone, the synthesized peptide is subsequently modified through covalent conjugation with a (PEG) moiety to enhance pharmacokinetic performance and resistance to enzymatic degradation, after assembly and pegylation, the peptide is released from the solid support, isolated, and subjected to purification to obtain a compound of high purity, then structural integrity and molecular identity of the final Pegylated TOP peptide are verified through analytical characterization techniques, confirming successful synthesis."
Disclaimer: Curated by HT Syndication.
